Our results showed that the combination of bevacizumab with either the FGF2-neutralizing antibody or PD-166866 significantly inhibited tumor growth and reduced the MVD in the bevacizumab-resistant HCT116 and HT-29 CRCLM xenografts (Supplemental Figure 9, A–C). Here, FGF2 is linked to neoplasm.